上海莱士：SR604注射液针IIb期临床试验已完成所有病人入组，预期明年上半年完成试验工作

Group 1 - The company Shanghai Laishi (002252.SZ) has completed the enrollment of all patients for the IIb clinical trial of SR604 injection, which is aimed at the prevention of bleeding episodes in patients with Hemophilia A/B and congenital factor VII deficiency [2] - The company expects to complete the trial work in the first half of next year [2]